Is Ocular Therapeuticx, Inc. (OCUL) Stock Positioned for Growth After Positive FDA Feedback on Axpaxli?
TheFly reported on June 18 that H.C. Wainwright increased its price target on OCUL to $25 from $21 while maintaining a Buy rating on the stock.
Ocular Therapeutix Inc (OCUL)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Levin Capital Strategies John A. Levin | 10,000 | $98,200 | 0.01% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $7.66 | 60,229 | $461,354.14 | 246,933 | 2026-02-20 | Filing | |
| $6.96 | 10,000 | $69,600.00 | 172,704 | 2025-05-08 | Filing | |
| $7.52 | 930,851 | $6,999,999.52 | 8,591,401 | 2024-02-26 | Filing | |
| $3.25 | 1,538,461 | $4,999,998.25 | 7,660,550 | 2023-12-14 | Filing | |
| $3.81 | 6,500 | $24,765.00 | 6,500 | 2023-08-30 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $8.27 | 14,828 | $122,627.56 | 300,079 | 2026-06-03 | Filing | |
| $8.20 | 21,156 | $173,479.20 | 2,597,170 | 2026-05-26 | Filing | |
| $8.20 | 2,967 | $24,329.40 | 266,141 | 2026-05-26 | Filing | |
| $8.20 | 3,018 | $24,747.60 | 320,350 | 2026-05-26 | Filing | |
| $8.20 | 1,858 | $15,235.60 | 328,795 | 2026-05-26 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 2,476,197 | $24,316,255 | 3.59% | |
| 2. | 871,692 | $8,560,015 | 0.48% | |
| 3. | 753,495 | $7,399,321 | 0.24% | |
| 4. | 385,000 | $3,780,700 | 0.09% | |
| 5. | 149,000 | $1,463,180 | 0.04% |
News See All
10 Best Healthcare Stocks to Buy According to Wall Street Analysts
The U.S. healthcare sector has significantly lagged the broader market for three consecutive years, returning just 0.3% in 2023, 0.9% in 2024, and 12.5% in 2025.
10 Best Biotech Stocks with Highest Upside Potential
On April 16, reports from J.P. Morgan's biopharma and medtech venture and licensing studies indicated that the capital markets began the year 2026 with selective strength.
Ocular Therapeutix (OCUL) Announces Additional Positive Data From the SOL-1 Phase 3 Superiority Trial of AXPAXLI
Ocular Therapeutix Inc. (NASDAQ:OCUL) is one of the best low priced biotech stocks to invest in. Ocular Therapeutix Inc.
8 Best Low Priced Biotech Stocks to Invest In
On April 16, Fundstrat’s Tom Lee appeared on CNBC's 'Closing Bell' to talk about what to expect from equity markets going forward.
10 Stocks With Easy 9-30% Upside
Sandisk climbed to a fresh all-time high on Thursday, as investors gobbled up shares following Bernstein SocGen Group’s 25-percent price target upgrade for its stock while positioning portfolios ahead...
7 Best Small-Cap Healthcare Stocks to Buy According to Hedge Funds
In this article, we will look at the best small-cap healthcare stocks to buy according to hedge funds.
Ocular Therapeutix, Inc. (OCUL): A Bull Case Theory
We came across a bullish thesis on Ocular Therapeutix, Inc. on r/Valueinvesting by Senior-Preference678. In this article, we will summarize the bulls’ thesis on OCUL.
Ocular Therapeutix, Inc. (OCUL): A Bull Case Theory
We came across a bullish thesis on Ocular Therapeutix, Inc. on TipRanks’ YouTube channel. In this article, we will summarize the bulls’ thesis on OCUL.
BofA Bullish on Ocular Therapeutix (OCUL) as AXPAXLI Targets Superiority Label and Faster Regulatory Path in Wet AMD
Ocular Therapeutix Inc. (NASDAQ:OCUL) is one of the low priced stocks to buy with high upside potential.
Hedge Fund Resource Center